Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 294

1.

Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.

Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL 3rd, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL.

JAMA Oncol. 2016 Nov 23. doi: 10.1001/jamaoncol.2016.5281. [Epub ahead of print]

PMID:
27893038
2.

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.

Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S.

Cancer Med. 2016 Nov 23. doi: 10.1002/cam4.956. [Epub ahead of print]

3.

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.

Kunos CA, Chu E, Beumer JH, Sznol M, Ivy SP.

Cancer Chemother Pharmacol. 2016 Nov 22. [Epub ahead of print]

PMID:
27878356
4.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.

Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM Jr, Blumenschein G Jr.

J Thorac Oncol. 2016 Nov 19. pii: S1556-0864(16)33473-6. doi: 10.1016/j.jtho.2016.11.2218. [Epub ahead of print]

PMID:
27876675
5.

Imaging biomarker roadmap for cancer studies.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC.

Nat Rev Clin Oncol. 2016 Oct 11. doi: 10.1038/nrclinonc.2016.162. [Epub ahead of print]

PMID:
27725679
6.

Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit.

Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, Epner D, Bruera E, Meric-Bernstam F, Falchook G, Subbiah V.

Oncology. 2016 Nov 2. [Epub ahead of print]

PMID:
27802448
7.

DNA Repair in Prostate Cancer: Biology and Clinical Implications.

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.

Eur Urol. 2016 Aug 31. pii: S0302-2838(16)30504-8. doi: 10.1016/j.eururo.2016.08.037. [Epub ahead of print] Review.

8.

Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.

Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J.

Ann Oncol. 2016 Nov;27(11):2032-2038.

PMID:
27573565
9.

Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobburu J.

Cancer Chemother Pharmacol. 2016 Nov;78(5):969. No abstract available.

PMID:
27677624
10.

Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobbru J.

Cancer Chemother Pharmacol. 2016 Nov;78(5):959-967. Erratum in: Cancer Chemother Pharmacol. 2016 Nov;78(5):969.

PMID:
27620207
11.

Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials.

George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS.

Cancer. 2016 Nov 15;122(21):3401-3409. doi: 10.1002/cncr.30182.

PMID:
27412379
12.

Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.

Castro E, Mateo J, Olmos D, de Bono JS.

Cancer J. 2016 Sep/Oct;22(5):353-356.

PMID:
27749330
13.

Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.

Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS.

Sci Rep. 2016 Oct 17;6:35448. doi: 10.1038/srep35448.

14.

Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.

Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM.

Int J Cancer. 2017 Jan 1;140(1):208-215. doi: 10.1002/ijc.30417.

PMID:
27599876
15.

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

Hong DS, Morris VK, Osta BE, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S.

Cancer Discov. 2016 Oct 11. [Epub ahead of print]

PMID:
27729313
16.

Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.

LeVasseur N, Clemons M, Hutton B, Shorr R, Jacobs C.

Cancer Treat Rev. 2016 Sep 20;50:183-193. doi: 10.1016/j.ctrv.2016.09.013. [Epub ahead of print] Review.

PMID:
27716496
17.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R.

Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026.

PMID:
27693888
18.

Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.

Carceller F, Bautista FJ, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Marshall LV, Vassal G, Pearson AD, Geoerger B, Moreno L.

Eur J Cancer. 2016 Nov;67:130-140. doi: 10.1016/j.ejca.2016.08.008.

PMID:
27662616
19.

Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer.

Heindl A, Lan C, Rodrigues DN, Koelble K, Yuan Y.

Oncotarget. 2016 Sep 19. doi: 10.18632/oncotarget.12106. [Epub ahead of print]

20.

Biliary cancer: Utility of next-generation sequencing for clinical management.

Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J.

Cancer. 2016 Sep 13. doi: 10.1002/cncr.30254. [Epub ahead of print]

PMID:
27622582
Items per page

Supplemental Content

Loading ...
Support Center